What Does Dynavax Technologies ($DVAX) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and HQ Summary
A hepatitis B vaccine specialist. HEPLISAV-B is growing rapidly. ~45% U.S. market share, FY2025 revenue of $315–325M. Acquisition by Sanofi (Q1 2026).
Subscribe🏢 What kind of company is Dynavax Technologies?
Dynavax Technologies Corp (DVAX) is a biotechnology company focused on vaccine development and commercialization, selling its flagship product, HEPLISAV-B (a hepatitis B vaccine), in the United States, Europe, and the UK. HEPLISAV-B delivers protection with a 3-dose regimen over 1 month instead of the conventional 3-dose regimen over 6 months required by existing hepatitis B vaccines, providing faster protective efficacy. It achieved approximately 45% U.S. market share in 2025, and its pipeline includes a shingles vaccine (Z-1018), a pandemic influenza vaccine, and a Lyme disease vaccine. The company will be integrated into a global vaccines franchise through its acquisition by Sanofi in January 2026.
💰 How does it make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| HEPLISAV-B (Hepatitis B Vaccine) | Approximately 98% | Adult hepatitis B vaccine; a rapidly growing product |
| Other Products / Licensing | Approximately 2% | Pipeline development and other revenue |
Quarterly revenue in 2025 came in at $330.5M, representing a year-over-year change of +26.7%. Total revenue in Q2 2025 rose 29% versus the prior-year period, with HEPLISAV-B net revenue increasing 31%, demonstrating strong growth. HEPLISAV-B revenue in Q3 2025 also grew 13%, indicating continued momentum. FY2025 HEPLISAV-B revenue guidance is tracking at a robust level.
📐 Market Capitalization and Company Scale
Market capitalization stands at $1.8B, and the company employs 405 people people.
As an innovation leader in the hepatitis B vaccine market, Dynavax has expanded market share through HEPLISAV-B's superior clinical profile and dosing convenience. The approximately 45% share of the U.S. market underscores accelerating adoption of HEPLISAV-B across the healthcare system. The shingles vaccine (Z-1018) in the pipeline addresses the preventive needs of an aging population for shingles protection, while the pandemic influenza and Lyme disease vaccines offer opportunities in emerging infectious-disease preparedness. Integration with Sanofi signals the expansion of a global distribution network.
📈 Dynavax Technologies Outlook and Stock Performance
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe vaccines market is a structurally growing segment, supported by population aging, the threat of emerging infectious diseases, and the rising importance of preventive medicine. HEPLISAV-B's high market share and increasing vaccine demand have laid the groundwork for Dynavax's medium- to long-term growth. However, regulatory shifts, competitive vaccine entries, and policy changes tied to infectious-disease outbreaks are factors to watch. Sanofi's acquisition (Q1 2026) signals the strengthening of a global vaccine portfolio and accelerated R&D.
⚔️ Key Competitive Strengths and Risks
HEPLISAV-B's high market share and robust growth are strengths, but intensifying competition and regulatory risks remain key challenges.
💪 Key Competitive Strengths
⚠️ Key Risks
🔄 Competitors and Related (Beneficiary) Stocks
Major competitors in the vaccines market include global pharmaceutical companies such as Merck (MRK), Sanofi (SNYNF), GSK (GSK), and Pfizer (PFE), as well as newer vaccine players like Moderna (MRNA) and BioNTech. Dynavax's strengths lie in HEPLISAV-B's differentiated clinical profile and high market share.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| MRK | Merck & Co Inc | $148.46 | -1.2% | $366.3B | 118.7 | 8.7 | 6.98% | 2.3% |
| SNY | Sanofi ADR | $43.15 | -2.5% | $102.9B | 22.2 | 1.3 | 5.7% | 5.68% |
| GSK | GSK Plc ADR | $48.54 | -2.7% | $97.3B | 15.3 | 4.2 | 29.69% | 3.86% |
| PFE | Pfizer Inc | $27.79 | -2.3% | $158.4B | 36.8 | 1.9 | 4.99% | 6.2% |
| MRNA | Moderna Inc | $140.33 | -3.6% | $56.0B | - | 8.3 | -39% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 XBI | State Street SPDR S&P Biotech ETF | $161.93 | -1.1% | $0.0M | - | - | - | 0.35% |
 IBB | iShares Biotechnology ETF | $207.33 | -2.2% | $0.0M | - | - | - | 0.2% |
| GILD | Gilead Sciences Inc | $146.64 | -2.9% | $181.8B | - | 15.4 | -20.57% | 2.22% |
| VRTX | Vertex Pharmaceuticals Inc | $528.90 | -3.1% | $134.1B | 30.8 | 6.6 | 23.54% | - |
✅ Investor Checklist
Dynavax Technologies has secured a leading position in the hepatitis B vaccine market on the back of strong HEPLISAV-B growth. The approximately 45% market share in 2025 and quarterly growth of 29–31% demonstrate robust market demand. Sanofi's acquisition (Q1 2026) signals global expansion and pipeline reinforcement, with the development of new products such as the shingles vaccine expected to be central to future growth.
| Checklist Item | What to Confirm | Current Status |
|---|---|---|
| 📈 HEPLISAV-B Revenue Trend | Quarterly revenue growth rate and changes in U.S. market share | Progress toward FY2025 target ($315–325M) |
| International Market Expansion | HEPLISAV-B sales growth in Europe, the UK, and other countries | Trend in the international revenue mix |
| Pipeline Progress | Z-1018 (shingles) Phase 1/2 progress and development of additional vaccines | Likelihood of new product launches |
Competitive vaccine launches, FDA regulatory changes, saturation of HEPLISAV-B market share, and integration risks from the Sanofi acquisition are the primary concerns. In particular, competing hepatitis B products from established pharmaceutical companies or the entry of new vaccine players could pressure growth rates.
Dynavax Technologies has emerged as a leader in the hepatitis B vaccine market, powered by strong HEPLISAV-B growth. The approximately 45% market share in 2025 and quarterly growth of 29–31% validate market receptivity for the innovative vaccine. Sanofi's acquisition (Q1 2026) enables the pooling of global resources and pipeline acceleration, and the successful commercialization of new products such as the shingles vaccine is expected to be key to long-term growth.
Check out Dynavax Technologies' real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free